Abstract
We investigated the effects of cilnidipine, a dihydropyridine derivative, on neuronal Ca++ channels in rat dorsal root ganglion neurons. Voltage-dependent Ca++-channel currents were recorded, using 5 mM Ba++ as the charge carrier, by means of the whole-cell patch-clamp technique. The Ba++current was subdivided pharmacologically into calciseptine-sensitive (L-type), ω-conotoxin GVIA- (ωCgTx) sensitive (N-type), ω-agatoxin IVA- (ωAgTx) sensitive (P/Q-type) and toxin-resistant currents. Cilnidipine inhibited the L-type current with an IC50 of 100 nM in neurons pretreated with ωCgTx plus ωAgTx. In neurons pretreated with Cal plus ωAgTx, cilnidipine induced a potent inhibition of the N-type current, but was unable to block the residual Ba++ current. The IC50 for cilnidipine in respect of the N-type current was 200 nM. Cilnidipine (300–500 nM) modified neither the voltage-dependent inactivation curve nor the decay of the N-type current. Furthermore, elevation of the holding potential did not enhance the inhibitory action of cilnidipine (300 nM) on the N-type current. No effect was induced by 100 nM cilnidipine on the P/Q-type current. However, nicardipine (1 μM) barely inhibited the N-type current at a concentration that almost completely blocked the L-type current. In conclusion, cilnidipine has potent inhibitory actions on N-type as well as L-type voltage-dependent Ca++-channel in rat dorsal root ganglion neurons. The former action may bestow an additional clinical advantage for the treatment of hypertension, such as suppression of reflex tachycardia.
Footnotes
-
Send reprint requests to: Dr. S. Fujii, Pharmaceuticals Research Laboratories, Fujirebio Inc., 51 Komiya-cho, Hachioji, Tokyo, 192, Japan.
- Abbreviations:
- DRG
- dorsal root ganglion
- VDCC
- voltage-dependent Ca++ channel
- DHP
- dihydropyridine
- Cal
- calciseptine
- ωCgTx
- ω-conotoxin GVIA
- ωAgTx
- ω-agatoxin IVA
- NE
- norepinephrine
- DMSO
- dimethylsulfoxide
- SHR
- spontaneously hypertensive rat
- Received August 5, 1996.
- Accepted November 26, 1996.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|